Eli Lilly and Co. is investing more than $700 million to enhance its global insulin manufacturing capacity in Indianapolis, PR, France and China. During the past year, Lilly has invested more than $1 billion in its manufacturing operations in response to the growing diabetes epidemic and increasing demand for insulin around the world.   Approximately half of the total investment will go to improvements at Indianapolis sites, where Lilly has been manufacturing insulin since 1923. In this latest e...